Treatment of Hypoparathyroidism With Subcutaneous PTH (1-84) Injections: Effects on Muscle Function and Quality of Life

Hypoparathyroidism Clinical Trial

— HypoPTH  

Official title:

Treatment of Hypoparathyroidism With Subcutaneous PTH (1-84) Injections: Effects on Muscle Function and Quality of Life

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00730210
• Other study ID #: EudraCT #008-000606-36)
• Status: Completed
• Phase: Phase 2
• First received: August 4, 2008
• Last updated: October 23, 2012
• Start date: June 2008
• Est. completion date: August 2010

Study information

• Verified date: October 2012
• Source: University of Aarhus
• Contact: n/a
• Is FDA regulated: No
• Health authority: Denmark: The Regional Committee on Biomedical Research Ethics
• Study type: Interventional

Clinical Trial Summary

The aim of the study is to assess whether PTH (1-84) therapy posses advantages compared to conventional treatment in patients with hypoparathyroidism on muscle function, quality of life, calcium homeostasis, bone metabolism, and body composition.

Description:

Hypoparathyroidism is one of the only hormonal insufficiency states that is usually not treated by replacing the missing hormone. Currently, Standard therapy includes treatment with calcium and an 1alpha-hydroxylated forms of vitamin D (e.g. calcitriol or alphacalcidol) in order to relieve the symptoms associated with hypocalcaemia. However, recent studies have shown that calcium homeostasis can be well regulated by PTH replacement therapy in patients with hypoparathyroidism. It seems that PTH treatment is safe and that it even may posses advantages compared to conventional treatment with vitamin D. As the renal calcium excretion is decreased by PTH therapy, the risk of renal calcifications causing an impaired renal function may be reduced. In addition, some of the hypoparathyroid patients treated with PTH reported less fatigue and increased endurance in response to treatment. This may be due to either a better regulated (i.e. more physiological) calcium homeostasis during PTH therapy, or due to a direct effect of PTH on the neuromuscular system. Therefore, further studies are needed on the effects of PTH replacement in patients with hypoparathyroidism.

Outcome measures:

• Muscle- and balance function: Effects of treatment on muscle strength and balance function are determined using a dynamometer and a stadiometer (Meititur Ltd, Finland). In addition, effects of treatment on muscle function are assessed through muscle biopsies, electromyographic, echocardiography, and by biochemical measures (muscle enzymes).

• Quality of life: Effect of treatment on indices of quality of life is assessed using the SF-36v2- and the WHO-Five Well-Being Index (WHO-5)-survey.

• Calcium homeostasis, bone metabolism, and body composition. Effects of treatment are assessed by measurements of calcitropic hormones, biochemical markers of bone turnover, and iliac crest biopsies. In addition, bone mineral density and body composition is measured.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 62
• Est. completion date: August 2010
• Est. primary completion date: August 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 25 Years to 80 Years

Eligibility

Inclusion Criteria:

• A low endogenous PTH production as verified by low plasma levels of intact PTH, necessitating treatment with 1alpha-hydroxylated vitamin D analogs.

• At least one years of continuous alphacalcidol, calcitriol, or dihydrotachysterol treatment prior to study entry.

• Prior to start of study, participants are required to have received a daily supplement of at least 400 IU (10 microgram) of vitamin D (ergocalciferol or cholecalciferol) for at least 3 months or 25hydroxyvitamin D levels above 50 nmol/l. Subjects may be treated with ergocalciferol or cholecalciferol during a run-in period of three months before entering the study.

• Normal plasma magnesium level (If not, magnesium supplements may be provided during a 3 months run in period).

• Plasma calcium levels within the normal reference range or slightly below (P-Ca ionized 1.00 to 1.30).

• Use of safe contraceptive methods (fertile women).

• Speak and read Danish.

Exclusion Criteria:

• Known allergic reactions to any of the compounds in the trial medication.

• Severely impaired renal function (plasma creatinine > 200 micromol/l).

• Severely impaired hepatic function (Plasma alanine aminotransferase (ALAT) > 100 U/l and/or alkaline phosphatase > 400 U/l).

• Previous or present malignancies (except a treated skin cancer that is not melanoma or treated carcinoma in situ, 2 years since last therapy).

• Prior radiation therapy involving the skeleton.

• Current treatment with raloxifene, calcitonin, systemic corticosteroids above 5 mg a day, fluoride, lithium, PTH, or digoxin.

• Treatment with anticonvulsant's (within the last 2 years).

• Immobilization (more than two week within the last 6 months).

• Granulomatous disease.

• Paget's disease of bone.

• Pregnancy / planned within the next year. Hospitalized due to chronic drug or alcohol abuse. Severe malabsorption syndrome.

• Major medical or social problems that will be likely to preclude participation for one year.

• Unwillingness to participate.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Hypoparathyroidism

Intervention

Drug:
• a: PTH (1-84)
preotact 100 microgram subcutaneous a day in 6 months
• b:placebo
100 microgram placebo subcutaneous a day for 6 months

Locations

Country	Name	City	State
Denmark	Osteoporoseklinikken, Aarhus University Hospital	Aarhus	Jutland

Sponsors (1)

Lead Sponsor	Collaborator
University of Aarhus

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Increase in maximal voluntary knee extension		6 months	No
Secondary	Balance function: Is assessed using a stadiometer (Meititur Ltd, Finland)		6 months	No
Secondary	Effect of treatment on indices of quality of life is assessed using the SF-36v2- and WHO-Five Well-Being Index (WHO-5)-survey.		6 months	No
Secondary	Effects of treatment on muscle function are assessed through muscle biopsies, electromyographic, and by biochemical measures (muscle enzymes).		6 months	No
Secondary	Bone mineral density and body composition is measured		6 months	No
Secondary	Calcium homeostasis and bone metabolism. Effects of treatment are assessed by measurements of calcitropic hormones, biochemical markers of bone turnover, and bone biopsies		6 months	No
Secondary	Q CT scan of hip and spine		6 months	No
Secondary	Effects of treatment on diurnal variations of measured biochemical indices, as assessed at the end of the treatment period		24 hours at the end of the 6 month treatment period	No
Secondary	Effects of treatment on indices of cardiovascular health (ECG and blood pressure), as measured at the end of the treatment period just prior to and 1 hour after injection of study medication.		at the end of the 6 months treatment period	Yes